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There is growing recognition that severe acute respira-
tory syndrome coronavirus-2 (SARS-CoV-2) infection 
can lead to both acute and long-term neurological seque-
lae [1]. In addition to the neurological consequences of 
severe illness in itself, proposed mechanisms of SARS-
CoV-2-associated neurological complications include 
direct neuroinvasion, and indirect mechanisms, of vas-
cular and inflammatory/autoimmune origin (Fig. 1). The 
identification and diagnosis of these neurological com-
plications are challenging, particularly in the context of 
overstrained medical systems, where an under-recogni-
tion of neurological manifestations may contribute to an 
increase in acute and long-term complications and poor 
outcomes. In addition, there is a high incidence of gen-
eral critical care complications, for example, hypoxia, 
metabolic derangements, general inflammation, and 
drug toxicity/side effects, which can make proper attri-
bution to coronavirus disease 2019 (COVID-19) difficult. 
We discuss the neurological complications associated 
with COVID-19 (NeuroCOVID) for general intensivists 
with an emphasis on key symptoms and signs to look for 
which may change management and/or provide a poten-
tial avenue for targeted therapies to improve outcomes.
In an early case series from Wuhan > 45% of COVID-19 
patients had neurological symptoms that involved both 
the central nervous system (i.e. anosmia/ageusia, altered 
mental status, stroke, and seizure) and the peripheral 
nervous system (i.e. muscle/nerve disease) (Supplemen-
tary Table 1) [2]. Subsequent multicentre studies revealed 
that encephalopathy (31–42%) and stroke syndromes 
(36–62%) account for most of the COVID-19-associated 
neurological complications, with inflammatory syn-
dromes, i.e. encephalitis (5–13%) and Guillain-Barré 
(5–9%) much less frequent [3, 4]. The overall incidence 
of ischemic stroke is relatively high. It tends to occur in 
younger patients, with more frequent large vessel occlu-
sion and higher mortality than described in patients 
without COVID-19[5] and those with influenza [6]. Of 
the common sequelae, stroke and inflammatory syn-
dromes seem to have the worst outcomes.
Delirium and coma are diagnosed in more than 50% 
and 80% of patients admitted to the intensive care unit 
(ICU) with COVID-19, respectively. Notably, a high 
exposure to sedatives, mainly benzodiazepines has been 
independently associated with higher rates of delirium 
[7]. After cessation of sedatives, patients with severe 
respiratory failure secondary to COVID-19 may have 
a prolonged period of unconsciousness which may be 
weeks before complete recovery [8]. Caution is therefore 
advised when prognosticating in these patients.
Abnormalities detected on neuroimaging in patients 
with COVID-19 who require critical care are described 
in Supplementary Table  2. The most common find-
ings include leukoencephalopathy, ischemia/infarction 
with patterns of large vessel occlusion, leptomeningeal 
enhancement, encephalitis, haemorrhage in locations 
not typical for hypertension (lobar and/or cortical; which 
raises the question of whether it is secondary to antico-
agulation), and perfusion abnormalities.
Microhaemorrhages are a frequent finding on suscep-
tibility-weighted imaging. They are particularly located 
in callosal and juxtacortical regions in a distribution dis-
tinct from other causes of similar lesions, including trau-
matic brain injury. Such microhaemorrhages have also 
been described in critically ill ventilated patients who 
do not have COVID-19, and it is unclear whether these 
may be secondary to COVID-19 itself or a complication 
of being critically ill with prolonged respiratory failure 
and hypoxemia [9]. For both microhaemorrhages and 
leukoencephalopathy, an association with microvascu-
lar disease has been described in post mortem studies of 
patients with COVID-19 [10]. Advanced magnetic reso-
nance imaging (MRI) using diffusion tensor imaging has 
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found abnormalities consistent with widespread oedema, 
including in crucial brainstem arousal nuclei in patients 
with persistent unresponsiveness [11]. These findings 
provide a potential explanation of prolonged altered sen-
sorium and mental status in patients with COVID-19.
There is a growing number of studies confirming that 
neuroprotective measures should be maintained in 
patients with COVID-19. In one retrospective study, 
measurement using ultrasound of the Optic Nerve 
Sheath Diameter (ONSD) found that 19% of patients 
potentially had raised intracranial pressure, which was 
associated with a longer stay in ICU [12]. Electroen-
cephalogram recordings obtained in critically ill patients 
also tend to be consistent with encephalopathy rather 
than non-convulsive status epilepticus and may suggest 
COVID-19 related brain injury [13].
Neurointensive care management during the first 
COVID-19 waves has required adaptations to existing 
protocols for common neurological emergencies, includ-
ing stroke, status epilepticus, neuroprotective strategies, 
venothromboembolism prophylaxis, and delirium man-
agement. Multimodal evaluation (MRI, cerebral spinal 
fluid analysis and electroencephalography) of COVID-19 
patients with persistent encephalopathy allowed identi-
fication of rare cases of COVID-19 associated encepha-
litis, mainly of immune-mediated origin (including 
brainstem or limbic encephalitis, and acute disseminated 
encephalitis). For those with likely neuroinflammatory 
Fig. 1 Schematic of potential mechanisms and complications of NeuroCOVID. Direct infection and replication via transsynaptic spread of periph-
eral and cranial nerves (e.g. vagal or olfactory nerves) or blood–brain barrier dysfunction may lead to the clinical syndromes of encephalitis, myelitis 
and meningitis (S1). However, given that detection of SARS-CoV-2 in CSF via Polymerase Chain Reaction (PCR) or intrathecal antibodies is rare, 
direct neuroinvasion is likely to account for only a minority of cases (S2). Neuroinflammation with entry to the CNS of cytokines is thought to occur 
(S1). Autoimmune neurological syndromes including acute disseminated encephalomyelitis, myelitis, and Guillain–Barre Syndrome have also been 
reported (S3). Endotheliopathy and/or hypercoagulability have been implicated in the pathogenesis of stroke secondary to COVID019 (S4, S5). PTSD 
post traumatic stress disorder. Image created with BioRender.com. References for the figure may be found in the Supplementary material
syndromes, there is a need for careful consideration of 
therapy, as cases of steroid-responsive encephalitis have 
been described [14]. In such patients, a combination of 
high-dose steroids and intravenous immunoglobulins or 
plasma exchange may be considered.
Many survivors of critical illness develop post inten-
sive care syndrome (PICS) which may cause cognitive, 
mental health, and physical impairments, with significant 
impacts on function and quality of life (Supplementary 
Fig.  1). The effects of this may be further compounded 
by post acute sequelae of COVID-19 (PASC), and so the 
rehabilitation needs of these patients may be significant 
[15]. Critical care recovery clinics with in-person and 
telehealth options have become valuable resources for 
ICU survivors and their families. The impact of COVID-
19 centres with multidisciplinary services to address the 
ongoing medical and rehabilitation needs of COVID-
19 survivors needs to be studied to guide hospitals and 
health systems in planning and preparing resources for 
millions of survivors. Unsurprisingly, given the trauma 
of a critical care admission, and the added stresses of the 
pandemic including a lack of family visits in many hospi-
tal systems, there is a high prevalence of post-traumatic 
stress symptoms [15].
There is a need to monitor patients with COVID-19 for 
neurological complications, at the acute phase and in the 
long term. In addition, those with a prolonged course of 
recovery will place additional burdens on overstretched 
systems. Ongoing studies will help identify patients at 
higher risk of developing neurological complications, 
streamline neuromonitoring strategies and guide man-
agement despite limitations on resources. Global col-
laboration and harmonization of such efforts will be 
important to facilitate rapid understanding of how best 
to manage the neurological complications of COVID-19, 
and so optimize outcomes.
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